Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Newsletter
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Newsletter
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors

Odylia Therapeutics is pleased to announce the appointment of Joy Cavagnaro to its Board of Directors....

12 March, 2025
Services
  • Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
  • Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors
Odylia Therapeutics logo

© 2024 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs